3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
64
Neoplasms
8
Sarcoma
6
Ovarian Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Sarcoma, Ewing
4
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Glioma
4
Carcinoma, Non-Small-Cell Lung
4
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Prostatic Neoplasms
3
Osteosarcoma
3
Neuroblastoma
3
Melanoma
3
Medulloblastoma
3
Lymphoma
3
Liposarcoma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Kidney Neoplasms
2
Interventions
Tamoxifen
12
Specimen Handling
6
Anastrozole
6
Chemotherapy, Adjuvant
5
Radiotherapy
4
Letrozole
4
afimoxifene
3
Mastectomy, Segmental
3
Surgical Procedures, Operative
2
Simvastatin
2
Radiation Dose Hypofractionation
2
Radiation
2
Fish Oils
2
Fatty Acids, Omega-3
2
4,17 beta-dihydroxy-4-androstene-3-one
2
telapristone acetate
1
sargramostim
1
ruxolitinib
1
polyphenon E
1
palbociclib
1
fezolinetant
1
exemestane
1
elacestrant
1
darolutamide
1
bazedoxifene
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
abemaciclib
1
Zoledronic Acid
1
Testosterone
1
Tea
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Intraductal, Noninfiltrating
×
palbociclib
×
Clear all
NCT03535506
2025-09-26
WI223281
Georgetown University
Phase 2
Terminated
17 enrolled
9 charts